TITLE

Immunotherapy with �-Amyloid for Alzheimer's Disease: A New Frontier

AUTHOR(S)
Schenk, Dale; Seubert, Peter; Ciccarelli, Richard B.
PUB. DATE
November 2001
SOURCE
DNA & Cell Biology;Nov2001, Vol. 20 Issue 11, p679
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Alzheimer's disease (AD) represents the fourth leading cause of death in the U.S. and the leading cause of dementia in the elderly population. Until recently, there was little hope of finding a way to prevent the underlying brain pathology from progressing toward the inevitable conclusion of the disease. However, new immunotherapeutic approaches have been described that are based on vaccination with the �-amyloid 1-42 peptide (A�). The encouraging efficacy and safety of A� immunization in reducing neuropathology in animal models of AD has opened up new therapeutic possibilities for patients. Immunization with A� is aimed at reducing the A�-associated pathology of AD. It is hypothesized that this approach will also reduce the cascade of downstream events leading to neuronal cell loss and, ultimately, dementia. The ensuing articles in this issue describe various aspects of the A� immunization strategy and their potential relevance to AD treatment.
ACCESSION #
5849368

 

Related Articles

  • Findings could spoil current approaches to an Alzheimer's cure.  // Long-Term Living: For the Continuing Care Professional;Apr2010, Vol. 59 Issue 4, p12 

    The article focuses on the recent study in "Biological Psychiatry" which states that amyloid beta protein that is consider one of the hallmarks of Alzheimer's disease patients is also present among healthy elderly people.

  • Preface. Nienaber, Vicki L. // Current Pharmaceutical Design;Dec2002, Vol. 8 Issue 28, p1 

    Introduces the articles published in the December 2002 issue of 'Current Pharmaceutical Design.' Biological details of the connection between Alzheimer's disease and �-amyloid plaque formation; Role of proteolytic enzymes in plaque formation; Description of inhibitors of the Hepatitis C...

  • Emerging �-Amyloid Therapies for the Treatment of Alzheimer's Disease. Conway, Kelly A.; Baxter, Ellen W.; Felsenstein, Kavin M.; Reitz, Allen B. // Current Pharmaceutical Design;Feb2003, Vol. 9 Issue 6, p427 

    Alzheimer's Disease (AD) is a progressive neurodegenerative disorder marked by loss of memory, cognition, and behavioral stability. AD is defined pathologically by extracellular neuritic plaques comprised of fibrillar deposits of �-amyloid peptide (A�) and neurofibrillary tangles...

  • beta-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer Disease Dream or Reality? Talaga, Patrice // Mini Reviews in Medicinal Chemistry;Jul2001, Vol. 1 Issue 2, p175 

    Amyloid (A beta) deposition remains a hallmark in the pathology of Alzheimer disease (AD). Important drug discovery efforts dedicated to the inhibition of the polymerization process leading to amyloid neurotoxicity are pursued by academic groups and the pharmaceutical industry as a potential...

  • Fragile minds. Motluk, Alison // New Scientist;2/1/2003, Vol. 177 Issue 2380, p34 

    Investigates the viability of proposed treatments of Alzheimer's disease. Role of the protein amyloid beta in the progress of the disease; Difference of opinion among researchers over the success of treatments that rely on the removal of amyloid beta; Possibility of the protein being...

  • Drug to prevent disease within reach? O'connor, John // McKnight's Assisted Living;Oct2011, Vol. 9 Issue 5, p4 

    The article offers information related to a research which attempts to prevent and treat Alzheimer's disease by inhibiting the accumulation of protein fibres and amyloid beta molecules.

  • Neurodegenerative disease: Putting the brakes on cognitive decline. Smith, Adam // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p507 

    Reports on a study appearing in the May 22, 2003 issue of 'Neuron,' which suggests that antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Immunoreactivity of human sera for aggregated beta-amyloid plaques; Generation of antibodies against aggregated beta-amyloid...

  • Alzheimer disease's double-edged vaccine. Greenberg, S. M.; Bacskai, B.J.; Hyman, B. T. // Nature Medicine;Apr2003, Vol. 9 Issue 4, p389 

    Describes the first autopsy of a brain from an alzheimer disease (AD) patient treated with an experimental amyloid-β (Aβ) vaccine. Uncertainty on the effectiveness of the vaccine against AD; Lesions unaffected by the vaccine; Side effects of the vaccine on patients.

  • Neuropathology of human Alzheimer disease after immunization with amyloid-b peptide: a case report. Nicoll, James A.R.; Wilkinson, David; Holmes, Clive; Steart, Phil; Markham, Hannah; Weller, Roy O. // Nature Medicine;Apr2003, Vol. 9 Issue 4, p448 

    Amyloid-β peptide (Aβ) has a key role in the pathogenesis of Alzheimer disease (AD). Immunization with Aβ in a transgenic mouse model of AD reduces both age-related accumulation of Aβ in the brain[SUP1] and associated cognitive impairment[SUP2,3]. Here we present the first analysis...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics